Our Rexahn Pharmaceuticals Stock Prediction In 2019 (Buy or Sell?)
Investing Daily
On the other hand, the stock has had a dreadful 2018, down about 45% through mid-November. A major negative catalyst was a direct sale of common stock and warrants totaling about 5.77 million shares to institutional investors. Rexahn did it to raise …
and more